<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0211976-8k_silexion.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>August 21, 2024 (August 15, 2024)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Silexion Therapeutics
Corp</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B></B></FONT>(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><B>Cayman Islands</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><B>001-42253</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><B>N/A</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 49%"><B>2 Hama&rsquo;ayan Street</B></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Modi&rsquo;in-Maccabim-Reut, Israel</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>7177871</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>+972-8-6286005<BR> </B>(Registrant&rsquo;s
telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Biomotion Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 34%"><B>Title of each class</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1.5pt; width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 31%"><B>Trading Symbol(s)</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><B>Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"><B>Ordinary Shares, par value $0.0001 per share</B></TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>SLXN</B></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><B>Warrants exercisable for Ordinary Shares at an exercise price of $11.50 per share</B></TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>SLXNW</B></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Introductory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">On August 15, 2024 (the &ldquo;Closing Date&rdquo;),
Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (the &ldquo;registrant&rdquo;) consummated
the previously announced transactions pursuant to that certain Amended and Restated Business Combination Agreement, dated as of April
3, 2024 (as amended, the &ldquo;Business Combination Agreement&rdquo;), by and among the registrant, Moringa Acquisition Corp (&ldquo;Moringa&rdquo;),
August M.S.&nbsp;Ltd., an Israeli company and a wholly-owned&nbsp;subsidiary of the registrant (&ldquo;Merger Sub 1&rdquo;), Moringa Acquisition
Merger Sub Corp, a Cayman Islands exempted company and a wholly-owned&nbsp;subsidiary of the registrant (&ldquo;Merger Sub 2&rdquo;),
and Silexion Therapeutics Ltd., an Israeli company (&ldquo;Silexion&rdquo;). The transactions contemplated by the Business Combination
Agreement are hereinafter referred to as the &ldquo;Business Combination.&rdquo; In connection with the consummation of the Business Combination
(the &ldquo;Closing&rdquo;), the registrant changed its name from &ldquo;Biomotion Sciences&rdquo; to &ldquo;Silexion Therapeutics Corp&rdquo;
(hereinafter referred to as &ldquo;New Silexion&rdquo; or &ldquo;New Pubco&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Unless the context otherwise requires, the &ldquo;Company&rdquo;,
&ldquo;we&rdquo;, &ldquo;us&rdquo; &ldquo;our&rdquo; and similar terms refer to the registrant, which is New Silexion after the Closing,
and Biomotion Sciences prior to the Closing. All references herein to the &ldquo;Board&rdquo; refer to the board of directors of New Silexion.
Terms used in this Current Report on Form 8-K (this &ldquo;Report&rdquo;) but not defined herein, or for which definitions are not otherwise
incorporated by reference herein, have the same meaning given to such terms in the final proxy statement/prospectus dated July 17, 2024
and filed by the Company with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on July 17, 2024 pursuant to Rule 424(b)(3)
under the Securities Act of 1933, as amended (the &ldquo;Proxy Statement/Prospectus&rdquo;), in the section entitled &ldquo;<I>Frequently
Used Terms</I>&rdquo; beginning on page 1 thereof, and such definitions are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to the Business Combination Agreement,
among other things, (i) Merger Sub 2 merged with and into Moringa, with Moringa continuing as the surviving company and a wholly-owned
subsidiary of New Silexion (the &ldquo;SPAC Merger&rdquo;) and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing
as the surviving company and a wholly-owned subsidiary of New Silexion (the &ldquo;Acquisition Merger&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Upon the effectiveness of the SPAC Merger, each
outstanding Moringa Class&nbsp;A ordinary share, par value $0.0001 per share (&ldquo;Moringa Class A ordinary shares&rdquo;) that had
not been redeemed and the sole outstanding Moringa Class&nbsp;B ordinary share, par value $0.0001 per share, converted into an ordinary
share of New Silexion, par value $0.0001 per share (a &ldquo;New Silexion ordinary share&rdquo;) on a one-for-one&nbsp;basis. Each outstanding
warrant to purchase one Moringa Class&nbsp;A ordinary share (&ldquo;Moringa warrant&rdquo;) converted into a warrant to purchase one New
Silexion ordinary share (&ldquo;New Silexion warrant&rdquo;), at the same exercise price. Upon the effectiveness of the Acquisition Merger,
each outstanding ordinary share and preferred share of Silexion converted into such number of New Silexion ordinary shares as is equal
to the quotient obtained by dividing (x)&nbsp;the quotient obtained by dividing (1)&nbsp;$62,500,000 by (2)&nbsp;the number of fully diluted
Silexion equity securities, by (y)&nbsp;$10.00 (the &ldquo;Silexion Equity Exchange Ratio&rdquo;). Each outstanding Silexion warrant and
Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for one Silexion
share, became exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary shares as are
equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion option
and Silexion warrant were adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio. The
terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs remain the same following such
conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition Merger, such that the New
Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised (on a cashless basis) immediately
prior to the Acquisition Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">In connection with the Moringa shareholder vote
to approve the Business Combination Agreement and the Business Combination, holders of an aggregate of 427,297 Moringa ordinary shares
properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust Account holding the proceeds from
the IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate. In addition, pursuant to an agreement reached by Moringa
with EarlyBird Capital, Inc. (&ldquo;EarlyBird&rdquo;), which served as the representative of the underwriters for Moringa&rsquo;s IPO,
on the reduction, of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated February&nbsp;16, 2021, by
and between Moringa and EarlyBird (the &ldquo;Marketing Agreement&rdquo;) (as described further below under &ldquo;Item 1.01&mdash; Agreement
with EarlyBird for Settlement of Amounts Due Under Marketing Agreement&rdquo;), Moringa paid $350,000 of cash to EarlyBird from the Trust
Account at the Closing. After the redemption payments, the payment to EarlyBird, and the satisfaction of amounts due to parties that arranged
financing and/or capital markets advisory services in connection with the Closing, the remaining balance of the Trust Account immediately
prior to the Closing of $333,936 was used to partially fund the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">As a result of the redemptions of Moringa ordinary
shares, a total of 87,722 Moringa public shares remained outstanding at the Closing. After giving effect to the Business Combination and
the following changes to share capital, immediately following the Closing, there were 9,768,396 New Silexion ordinary shares issued and
outstanding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the redemption of the 427,297 Moringa public shares described above;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of 87,722 New Silexion ordinary shares in exchange for
an equivalent number of Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions described
above);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the separation of each former Moringa unit into one Moringa Class A ordinary share and one-half of a Moringa warrant;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Sponsor Founder Shares Forfeiture of 1,308,000 Moringa founders shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Sponsor&rsquo;s transfer to third parties (in lieu of forfeiting) of all 1,567,000 Moringa founders shares that had been designated
to serve as Backstop Shares under the Business Combination Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of 380,000 New Silexion ordinary shares to the Moringa
Sponsor and EarlyBird, in the aggregate, in exchange for an equivalent number of Moringa private shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of an aggregate of 100,000 New Silexion ordinary shares
to EarlyBird and its designees in exchange for an equivalent number of representative shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance by New Pubco to the Sponsor and/or its limited partners to whom the Sponsor distributed such shares of the 1,382,325
Sponsor Investment Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of 200,000 New Silexion ordinary shares to Greenstar,
LP in exchange for an equivalent number of Moringa shares that were purchased in a private placement in connection with the closing of
the Business Combination;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of 4,024,942 New Silexion ordinary shares as the Silexion
Merger Consideration to securityholders of Silexion;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the issuance of 1,835,733 New Silexion ordinary shares to Guangzhou
Sino-Israel&nbsp;Bio-Industry&nbsp;Investment Fund I (&ldquo;GIBF&rdquo;), a security holder of Silexion, in consideration for its transfer
of its noncontrolling interest in Silexion&rsquo;s Chinese subsidiary, Silenseed (China) Ltd., to New Silexion, whereby that Chinese subsidiary
became a wholly-owned&nbsp;subsidiary of New Silexion (the &ldquo;Chinese Subsidiary Transfer&rdquo;) (in addition to 151,349 New Silexion
ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
issuance of 39,325 New Silexion ordinary shares to a non-employee director of New Pubco upon acceleration of vesting, and settlement,
of an equivalent number of New Silexion RSUs granted to the director.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The New Silexion ordinary shares and New Silexion
warrants commenced trading on the Nasdaq Global Market (&ldquo;Nasdaq&rdquo;) under the symbols &ldquo;SLXN&rdquo; and &ldquo;SLXNW&rdquo;,
respectively, on August 16, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">A more detailed description of the Business Combination
is included in the section entitled &ldquo;<I>Proposal No. 1 &mdash; The Business Combination Proposal</I>&rdquo; of the Proxy Statement/Prospectus
and is incorporated by reference herein. Further, the foregoing summary description of the Business Combination Agreement, as amended,
is qualified in its entirety by reference to the Business Combination Agreement, as amended by a waiver letter dated June 18, 2024, copies
of which are attached to this Report as Exhibits 2.1.1 and 2.1.2 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">This Report incorporates by reference certain
information from reports and other documents that were previously filed with the SEC, including certain information from the Proxy Statement/Prospectus.
To the extent there is a conflict between the information contained in this Report and the information contained in such prior reports
and documents and incorporated by reference herein, you should rely on the information in this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 1.01</B> <B>Entry into a Material Definitive Agreement.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Settlement of Amounts Due Under Marketing Agreement with EarlyBird
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Prior to the Closing, Moringa reached agreement
with EarlyBird on the reduction, to $1.6 million, in the aggregate, of the fee payable to EarlyBird under the Marketing Agreement entered
into by Moringa with EarlyBird at the time of Moringa&rsquo;s IPO. Pursuant to the final invoice provided by EarlyBird under the Marketing
Agreement at the Closing, Moringa paid $350,000 of cash to EarlyBird from the Trust Account at the Closing, and New Pubco issued to EarlyBird
a convertible promissory note, due December 31, 2025, in an amount of $1.25 million to be paid by New Pubco to EarlyBird in cash and/or
via conversion of outstanding amounts into ordinary shares of New Pubco (the &ldquo;EarlyBird Convertible Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The EarlyBird Convertible Note bears interest
at a rate of 6% per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to
which the repayment obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest
applicable to the unpaid principal amount would be adjusted to (15%) per annum. New Silexion is required to make mandatory prepayments
on the note (which shall first be applied to accrued interest and then to principal) from time to time in amounts equal to ten percent
(10%) of the gross proceeds received by New Silexion from any equity financings consummated by it prior to the maturity date. New Silexion
is entitled to voluntarily prepay any additional part of, or all of, the principal and accrued interest, in one or more installments without
penalty, prior to the maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">EarlyBird, in turn, may elect, at its sole discretion,
at any time on or prior to the Maturity Date, to elect to convert all or part of the then outstanding principal and/or accrued interest
under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume weighted
average price of a New Silexion ordinary share of New Silexion for the five trading days immediately prior to the date of New Silexion&rsquo;s
receipt of a conversion notice, provided, however, New Silexion is not required to issue, and EarlyBird may not elect to convert the principal
and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum number of ordinary shares
permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of New Silexion&rsquo;s shareholders, unless such
approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Under the EarlyBird Convertible Note, New Pubco
agreed to promptly file a registration statement with the SEC covering the resale of the ordinary shares that may be issued upon conversion
of the note and use its best efforts to have such registration statement declared effective as soon thereafter as possible. In the event
such registration statement is not declared effective by the SEC within 180 days from the date hereof, then an event of default shall
have occurred under the note, triggering all amounts under the note to become due and payable immediately and automatically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing summary provides only a brief description
and does not purport to be complete. The summary is qualified in its entirety by the full text of the final invoice provided by EarlyBird
under the Marketing Agreement at the Closing, and the EarlyBird Convertible Note, which serve as Exhibits 10.1.1 and 10.1.2 to this Report,
and which are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PIPE Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In connection with, and immediately prior to
the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the &ldquo;PIPE
Financing&rdquo;), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the &ldquo;PIPE Investor&rdquo;), 200,000
newly issued Moringa ordinary shares at a price of $10.00 per share, pursuant to a subscription agreement, dated as of August 15, 2024,
by and among Moringa, New Silexion and the PIPE Investor (the &ldquo;PIPE Agreement&rdquo;). Those 200,000 shares automatically converted
upon the Closing of the Business Combination into an equivalent number of New Silexion ordinary shares (the &ldquo;PIPE Shares&rdquo;).
The PIPE Investor is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which
New Silexion has agreed that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the
resale of the PIPE Shares by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared
effective by 180 days after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The funds raised from the PIPE Financing, together
with remaining funds in Moringa&rsquo;s Trust Account after payments to redeeming public shareholders, were used for financing support
for Moringa and New Pubco, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties
that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing summary provides only a brief description
of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text of the PIPE Agreement,
a copy of which is attached as Exhibit 10.2 to this Report, and which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ELOC Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Also in connection with the Closing, New Silexion
entered into an ordinary share purchase agreement, dated August 13, 2024, but effective as of the Closing Date (the &ldquo;ELOC Agreement&rdquo;),
for an equity line of credit (the &ldquo;ELOC&rdquo;) with White Lion Capital, LLC (the &ldquo;ELOC Investor&rdquo;), whereby New Pubco
will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private placement transactions,
up to $15.0 million of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement
is terminated sooner), subject to certain limitations and conditions as described therein. The number of New Silexion ordinary shares
that New Pubco may require the ELOC Investor to purchase in any single sales notice will depend on a number of factors, including the
type of purchase notice that New Pubco delivers.&nbsp; Similarly, the purchase price to be paid by the ELOC Investor for any shares that
New Pubco requires it to purchase will depend on the type of sales notice that New Pubco delivers, and will be derived from the market
price of the New Silexion ordinary shares for a certain period of time prior to New Silexion&rsquo;s purchase request or as of the date
of New Silexion&rsquo;s purchase request. New Pubco has also granted registration rights to the ELOC Investor pursuant to an accompanying
registration rights agreement, also dated August 15, 2024, by and between New Silexion and the ELOC Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to the ELOC Agreement, New Silexion
agreed, among other things, that if New Silexion&rsquo;s sales to the ELOC Investor under the ELOC exceed 19.99% of New Silexion&rsquo;s
total number of ordinary shares outstanding, New Silexion will seek the approval of its shareholders for the issuance of any New Silexion
ordinary shares under the ELOC in excess of that amount, in accordance with the Nasdaq Listing Rules, subject to certain exceptions based
on the price of the New Silexion ordinary shares to be sold in excess of that limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In consideration for the commitments of the ELOC Investor, New Pubco
agreed to issue to the ELOC Investor an aggregate of $337,500 of New Silexion ordinary shares (the &ldquo;ELOC Commitment Shares&rdquo;)
based on the closing price of the New Silexion ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness
of the registration statement registering the resale of the shares issuable under the ELOC ordinary share purchase agreement and (ii)
the business day prior to the 180<SUP>th</SUP> day following the Closing Date of the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Under the accompanying registration rights agreement,
dated August 13, 2024, but effective as of the Closing Date, by and between New Silexion and the ELOC Investor (the &ldquo;ELOC Registration
Rights Agreement&rdquo;), New Silexion has agreed to register the resale of the New Silexion ordinary shares that may be sold pursuant
to the ELOC, along with the ELOC Commitment Shares, within 45 days following the Closing Date, via a registration statement on Form S-1
to be filed with the SEC, and to use its commercially reasonable efforts to have that registration statement declared effective by the
SEC as soon as reasonably practicable following the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing summaries provide only a brief
description of the ELOC Agreement and ELOC Registration Rights Agreement. The summaries do not purport to be complete and are qualified
in their entireties by the full text of such documents, copies of which are attached as Exhibits 10.3.1 and 10.3.2, respectively, to this
Report, and which are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Amended and Restated Registration Rights and Lock-Up Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Prior to the Closing under the Business Combination
Agreement, on August 14, 2024, New Pubco, Moringa, Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of Silexion&rsquo;s
pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) an Amended and Restated Registration
Rights and Lock-Up&nbsp;Agreement which became effective as of the Closing (the &ldquo;A&amp;R Registration Rights and Lock-Up Agreement&rdquo;).
Under the agreement, New Pubco has assumed Moringa&rsquo;s existing obligations under Moringa&rsquo;s prior registration rights agreement
(entered into in connection with its IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment
Shares, certain of Silexion&rsquo;s pre-Business Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities
of New Pubco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Under the A&amp;R Registration Rights and Lock-Up
Agreement, New Pubco has agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain
minimum size offerings) and piggy-back&nbsp;rights on primary and secondary offerings, subject to customary cut-back&nbsp;provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Under the lock-up&nbsp;provisions of the agreement,
lock-up&nbsp;periods will apply following the Closing to securities of New Pubco that are held by the holders who are party to the agreement,
subject to permitted transfers to certain categories of &ldquo;Permitted Transferees&rdquo;. Specifically, those lock-up&nbsp;periods
will apply to the following categories of securities for the following periods of time post-Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>Sponsor Investment Shares and securities held by former
Silexion shareholders</I>: (A)&nbsp;50% of the Sponsor Investment Shares held by the Sponsor and its distributees
and 50% of the New Pubco securities held by the former Silexion shareholders who are party to the agreement, in each case, upon the Closing,
are subject to a lock-up&nbsp;period ending on the earlier of (i)&nbsp;six (6)&nbsp;months after the completion of the Business Combination,
and (ii)&nbsp;the date on which New Pubco will consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other
similar transaction after the Business Combination that results in all of New Pubco&rsquo;s shareholders having the right to exchange
their ordinary shares for cash, securities or other property, and (B)&nbsp;the other 50% of the Sponsor Investment Shares held by the
Sponsor and its distributees and 50% of the New Pubco securities held by the former Silexion shareholders party to the agreement, in
each case, upon the Closing, will be subject to a lock-up&nbsp;period that will end on the earliest of (x)&nbsp;six (6)&nbsp;months after
the date of the consummation of the Business Combination, (y)&nbsp;the date on which New Pubco consummates a liquidation, merger, amalgamation,
share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Pubco&rsquo;s
shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z)&nbsp;the date on which
the last reported sale price of New Pubco&rsquo;s ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share
dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20&nbsp;trading days within any 30-trading&nbsp;day
period.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>Private Shares
                                            and Private Warrants:</I> The lock-up&nbsp;period on all New Silexion ordinary shares issued
                                            pursuant to the SPAC Merger in exchange for private placement shares and private placement
                                            warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa&rsquo;s
                                            initial public offering will remain (as provided in the documentation for Moringa&rsquo;s
                                            initial public offering) 30&nbsp;days after the Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>Representative Shares</I>. The lock-up&nbsp;period on all Representative Shares (as defined in
                                                                                      the Amended and Restated Registration Rights and Lock-Up&nbsp;Agreement) that are held by EarlyBird will remain (as provided in the
                                                                                      documentation for Moringa&rsquo;s initial public offering) three&nbsp;months after the Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><I>Note&nbsp;Shares and PIPE Shares</I>. Note Shares issued to the Sponsor upon conversion of
                                                                                      amounts due under the A&amp;R Sponsor Promissory Note and PIPE Shares issued to the PIPE Investor will not be subject to any
                                                                                      lock-up&nbsp;periods following the Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing summary provides only a brief description
of the A&amp;R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in its entirety
by the full text of the A&amp;R Registration Rights and Lock-Up Agreement, a copy of which is attached as Exhibit 10.4 to this Report,
and which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Amended and Restated Sponsor Promissory Note</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Effective as of the Closing, New Pubco issued
to the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to New Pubco
upon the Closing), an amended and restated promissory note (the &ldquo;A&amp;R Sponsor Promissory Note&rdquo;) in an amount of $3,433,000,
which reflected the total amount owed by Moringa to the Sponsor through the Closing Date. The maturity date of the A&amp;R Sponsor Promissory
Note is the 30-month&nbsp;anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&amp;R Sponsor Promissory
Note may be repaid (unless otherwise decided by New Pubco) only by way of conversion into New Silexion ordinary shares (&ldquo;Note Shares&rdquo;)
in accordance with the terms set forth in the form of A&amp;R Sponsor Promissory Note. New Pubco and the Sponsor may also convert amounts
outstanding under the A&amp;R Sponsor Promissory Note at the price per share at which New Pubco conducts an equity financing following
the Closing, subject to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of
the number of New Silexion ordinary shares issued and sold by New Pubco in such equity financing. The Sponsor may also elect to convert
amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month&nbsp;anniversary
of the Closing Date, subject to a minimum conversion of $10,000, at a price per share equal to the volume weighted average price of the
New Silexion ordinary shares on the principal market on which they are traded during the 20 consecutive&nbsp;trading days prior to the
conversion date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing summary provides only a brief description
of the A&amp;R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the full text
of the A&amp;R Sponsor Promissory Note, a copy of which is attached as Exhibit 10.5 to this Report, and which is incorporated herein by
reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Indemnification Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">On the Closing Date, in connection with the Closing,
the Company entered into indemnification agreements with each of its directors and executive officers, which provide for indemnification
and advancements by the Company of certain expenses and costs under certain circumstances. The indemnification agreements provide that
New Silexion will indemnify each of its directors and executive officers against any and all expenses incurred by that director or executive
officer because of his or her status as a director or officer of New Silexion, to the fullest extent permitted under Cayman law, and the
Amended and Restated Memorandum and Articles (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The foregoing description of the indemnification
agreements does not purport to be complete and is qualified in its entirety by reference to the text of the form of Indemnification Agreement,
which is filed as Exhibit 10.6 to this Report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrant Assignment, Assumption and Amendment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">On the Closing Date, Moringa, New Silexion and
Continental Stock Transfer &amp; Trust Company (&ldquo;CST&rdquo;) entered into that certain Assignment, Assumption and Amendment Agreement
(the &ldquo;New Warrant Agreement&rdquo;). The New Warrant Agreement amends that certain Warrant Agreement, dated as of February 19, 2021,
by and between Moringa and CST (the &ldquo;Existing Warrant Agreement&rdquo;), to provide for the assignment by Moringa of all its rights,
title and interest in the warrants of Moringa to New Silexion. Pursuant to the New Warrant Agreement, all Moringa warrants under the Existing
Warrant Agreement will no longer be exercisable for Moringa ordinary shares, but instead will be exercisable for New Silexion ordinary
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The foregoing description of the New Warrant
Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the New Warrant Agreement, which
is filed as Exhibit 4.1 hereto and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Adoption of 2024 Equity Incentive
Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Reference is made to the disclosure regarding
the New Silexion (formerly referred to as the Biomotion Sciences) 2024 Equity Incentive Plan (the &ldquo;2024 Incentive Plan&rdquo;),
which is set forth under the heading &ldquo;<I>2024 Incentive Plan</I>&rdquo; in Item 5.02 of this Report, and which is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 2.01 Completion of Acquisition
or Disposition of Assets.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The disclosure set forth in the &ldquo;<I>Introductory
Note</I>&rdquo; above is incorporated by reference into this Item 2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">On August 6, 2024, Moringa held an extraordinary
general meeting (the &ldquo;extraordinary meeting&rdquo;), at which Moringa&rsquo;s shareholders considered and voted in favor of, among
other matters, a proposal to approve, as an ordinary resolution under Cayman Islands law, Moringa&rsquo;s entry into the Business Combination
Agreement and all transactions to be completed thereunder. On August 15, 2024, the parties to the Business Combination Agreement consummated
the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FORM 10 INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Item 2.01(f) of Form
8-K states that if the registrant was a &ldquo;shell company&rdquo; (as such term is defined in Rule 12b-2 under the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)), as the Company was immediately before the Business Combination, then the registrant
must disclose the information that would be required if the registrant were filing a general form for registration of securities on Form
10. As a result of the consummation of the Business Combination, and as discussed below in Item 5.06 of this Report, the Company has ceased
to be a shell company. Accordingly, the Company is providing the information below that would be included in a Form 10 if the Company
were to file a Form 10. Please note that the information provided below relates to the combined company after the consummation of the
Business Combination, unless otherwise specifically indicated or the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Certain statements in
this Report, including in the information that is incorporated by reference in this Report, may constitute &ldquo;forward-looking statements&rdquo;
for purposes of the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the
Company&rsquo;s and the Company&rsquo;s management team&rsquo;s expectations, hopes, beliefs, intentions or strategies regarding the future,
including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of
management for future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo;
&ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo;
&ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this Report may include, for example, statements
about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to recognize the expected benefits
of the Business Combination;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the ability to maintain the listing of the New Silexion ordinary
shares and warrants on Nasdaq following the Business Combination;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the future performance of the Company following the Business
Combination, including Silexion&rsquo;s projected timeline for regulatory approvals of its product candidates;&nbsp;;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s market opportunity;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the Company&rsquo;s strategy, future operations, financial
position, projected costs, prospects and plans;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">expectations regarding the time during which the Company
will be an emerging growth company under the JOBS Act;</TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the expected U.S. federal income tax impact of the Business
Combination;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the Company&rsquo;s ability to retain or recruit officers,
key employees and directors following the completion of the Business Combination;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the impact of the regulatory environment and complexities
with compliance related to such environment;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">expectations regarding future partnerships or other relationships
with third parties; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the Company&rsquo;s future capital requirements and sources
and uses of cash, including the Company&rsquo;s ability to obtain additional capital in the future.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The forward-looking statements contained in this
Report and in any document incorporated by reference are based on current expectations, forecasts and beliefs concerning future developments
and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that
the Company has anticipated. These forward-looking statements involve a number of risks, uncertainties, some of which are beyond the Company&rsquo;s
control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Silexion is a development-stage&nbsp;company and has a limited
operating history on which to assess its business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company has never generated any revenue from product sales
and may never be profitable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company will need to raise substantial additional funding,
which may not be available on acceptable terms, or at all, and which will cause dilution to its shareholders;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the approach Silexion is taking to discover and develop novel
RNAi therapeutics is unproven for oncology and may never lead to marketable products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Silexion does not have experience producing its product candidates
at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates,
and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Silexion may be unable to attract, develop and/or retain its
key personnel or additional employees required for its development and future success;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company may issue additional New Silexion ordinary shares
or other equity securities without your approval, including shares underlying warrants and Note&nbsp;Shares, which would dilute your
ownership interest and may depress the market price of the New Silexion ordinary shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">those additional factors described or incorporated by reference
under the heading &ldquo;<I>Risk Factors</I>&rdquo; below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Should one or more of these risks or uncertainties
materialize, or should any of the Company&rsquo;s assumptions prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. It is not possible to predict or identify all such risks. Accordingly, forward-looking
statements in this Report and in any document incorporated herein by reference should not be relied upon as representing the Company&rsquo;s
views as of any subsequent date, and the Company undertakes no obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The business of the Company is described in the
Proxy Statement/Prospectus in the section entitled &ldquo;<I>Information About Silexion</I>&rdquo; beginning on page 159 thereof, and
that information is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risk Factors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0.5in">The risks associated with the Company&rsquo;s
(and Silexion&rsquo;s) business, including Financial Condition and Capital Requirements<B>, </B>Research and Development of Silexion&rsquo;s
Product Candidates, Risks Related to Silexion&rsquo;s Reliance on Third Parties<B>, </B>Risks Related to Commercialization of Silexion&rsquo;s
Product Candidates, Risks Related to Competition, Risks Related to Silexion&rsquo;s Intellectual Property<B>, </B>Risks Related to Silexion&rsquo;s
Human Resources, Risks Related to Silexion&rsquo;s Operations, and Risks Relating to Silexion&rsquo;s Operations in Israel&nbsp;and China,
are described in the Proxy Statement/Prospectus in the section entitled &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 49 thereof
and are incorporated herein by reference. A summary of the risks associated with the Company&rsquo;s business are also described beginning
on page 42 of the Proxy Statement/Prospectus under the heading &ldquo;<I>Summary of the Proxy Statement/Prospectus &mdash; Risk Factors
Summary</I>&rdquo; and is incorporated by reference herein. There are no material changes to the Risk Factors section except for the additional
risk factors set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Owning New Silexion Ordinary Shares Following
the Business Combination and the Company Operating as a Public Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B><I>A substantial number of our ordinary shares
may be issued pursuant to the conversion terms of the Company&rsquo;s convertible notes (consisting of the A&amp;R Sponsor Promissory
Note and the EarlyBird Convertible Note), which could cause the price of the ordinary shares to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Amounts outstanding under each of the A&amp;R
Sponsor Promissory Note and the EarlyBird Convertible Note (collectively, the &ldquo;Convertible Notes&rdquo;) are convertible into our
ordinary shares, at conversion prices that relate to the market price of our ordinary shares and/or the price at which we raise capital
from equity financings. The issuance of any of these shares will dilute our other equity holders, which could cause the price of our ordinary
shares to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B><I>The requirement that we repay the EarlyBird
Convertible Note could adversely affect our business plan, liquidity, financial condition, and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">If not converted, we are required to repay principal
that is outstanding under the EarlyBird Convertible Note, as well as interest thereon, in connection with equity financings by us, or
upon the maturity of the note on December 31, 2025. That obligation could have important consequences on our business. In particular,
it could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">limit our flexibility in planning the payment of expenditures
that arise in our clinical program and our business and operations generally;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">increase our vulnerability to general adverse economic conditions
that hinder our ability to obtain equity financings; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">place us at a competitive disadvantage compared to our competitors.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">No assurances can be given that we will be successful
in making the required payments under the EarlyBird Convertible Note. If we are unable to make the required cash payments, there could
be a default under the EarlyBird Convertible Note. In such event, or if a default otherwise occurs under the EarlyBird Convertible Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the interest rate payable under the EarlyBird Convertible
Note could be increased, and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and
interest to be due and payable; and/or</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">we could be forced into bankruptcy or liquidation.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I></I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B><I>It is not possible to predict the actual
number of New Silexion ordinary shares, if any, we will sell under the ELOC Agreement to the ELOC Investor or the gross proceeds we will
receive from such sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">We generally have the right to control the timing
and amount of any sales of New Silexion ordinary shares to the ELOC Investor under the ELOC Agreement. Sales of New Silexion ordinary
shares, if any, to the ELOC Investor under the ELOC Agreement will depend upon market conditions and other factors to be determined by
us. We may ultimately decide to sell to the ELOC Investor all, some or none of the New Silexion ordinary shares that may be available
for us to sell to the ELOC Investor pursuant to the ELOC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Because the purchase price per share of New Silexion
ordinary shares to be paid by the ELOC Investor will fluctuate based on the market price of the New Silexion ordinary shares at the time
we elect to sell New Silexion ordinary shares, if any, to the ELOC Investor pursuant to the ELOC Agreement, it is not possible for us
to predict, as of the date of this Report and prior to any such sales, the number of New Silexion ordinary shares that we will sell to
ELOC Investor under the ELOC Agreement, the purchase price per share that ELOC Investor will pay for New Silexion ordinary shares purchased
from us under the ELOC Agreement, or the aggregate gross proceeds that we will receive from those purchases by ELOC Investor under the
ELOC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The number of New Silexion ordinary shares ultimately
offered for resale by the ELOC Investor is dependent upon the number of New Silexion ordinary shares, if any, we ultimately elect to sell
to ELOC Investor under the ELOC Agreement. However, even if we elect to sell New Silexion ordinary shares to the ELOC Investor pursuant
to the ELOC Agreement, the ELOC Investor may resell all, some or none of such shares at any time or from time to time in its sole discretion
and at different prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Because the purchase price per share to be paid
by the ELOC Investor for the New Silexion ordinary shares that we may elect to sell to the ELOC Investor under the ELOC Agreement, if
any, will fluctuate based on the market prices of our New Silexion ordinary shares for each purchase (if any) made pursuant to the ELOC
Agreement, it is not possible for us to predict, as of the date of this Report and prior to any such sales, the number of New Silexion
ordinary shares that we will sell to ELOC Investor under the ELOC Agreement, the purchase price per share that the ELOC Investor will
pay for shares purchased from us under the ELOC Agreement, or the aggregate gross proceeds that we will receive from those purchases by
the ELOC Investor under the ELOC Agreement, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Any issuance and sale by us under the ELOC Agreement,
or the resale by the ELOC Investor under the related resale registration statement that we are required to file for it under ELOC Agreement,
of a substantial amount of New Silexion ordinary shares could cause additional substantial&nbsp;dilution&nbsp;to our shareholders. The
number of New Silexion ordinary shares ultimately offered for sale by ELOC Investor is dependent upon the number of New Silexion ordinary
shares, if any, we ultimately sell to the ELOC Investor under the ELOC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B><I>The sale and issuance of New Silexion ordinary
shares to the ELOC Investor will cause&nbsp;dilution&nbsp;to our existing securityholders, and the resale of the New Silexion ordinary
shares acquired by the ELOC Investor, or the perception that such resales may occur, could cause the price of our New Silexion ordinary
shares to decrease.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The purchase price per share of New Silexion
ordinary shares to be paid by the ELOC Investor for the New Silexion ordinary shares that we may elect to sell to ELOC Investor under
the ELOC Agreement, if any, will fluctuate based on the market prices of our New Silexion ordinary shares at the time we elect to sell
New Silexion ordinary shares to ELOC Investor pursuant to the ELOC Agreement. Depending on market liquidity at the time, resales of such
New Silexion ordinary shares by ELOC Investor may cause the trading price of our New Silexion ordinary shares to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">If and when we elect to sell New Silexion ordinary
shares to the ELOC Investor, sales of newly issued New Silexion ordinary shares by us to the ELOC Investor could result in substantial&nbsp;dilution&nbsp;to
the interests of existing holders of our New Silexion ordinary shares. Additionally, the sale of a substantial number of New Silexion
ordinary shares to the ELOC Investor, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B><I>Investors who buy shares at different times
from the ELOC Investor will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to the ELOC Agreement, we will have discretion,
subject to market demand, to vary the timing, prices, and numbers of shares sold to the ELOC Investor. If and when we do elect to sell
New Silexion ordinary shares to the ELOC Investor pursuant to the ELOC Agreement, after the ELOC Investor has acquired such shares, the
ELOC Investor may resell all, some or none of such shares at any time or from time to time in its discretion and at different prices.
As a result, investors who purchase shares from the ELOC Investor in this offering at different times will likely pay different prices
for those shares, and so may experience different levels of&nbsp;dilution&nbsp;and in some cases substantial&nbsp;dilution&nbsp;and different
outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the ELOC Investor
as a result of future sales made by us to the ELOC Investor at prices lower than the prices such investors paid for their shares from
the ELOC Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The unaudited condensed consolidated financial
statements of Silexion as of June 30, 2024, and for the three and six months ended, June 30, 2024 and 2023, are attached as Exhibit 99.1
to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The audited consolidated financial statements
of Silexion as of December 31, 2023 and 2022, and for the years ended December 31, 2023 and 2022, are included in the Proxy Statement/Prospectus
beginning on page F-52 thereof and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The unaudited pro forma condensed combined financial
information of the Company is attached as Exhibit 99.2 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations of Silexion Therapeutics Ltd. for the three and six months periods ended June 30, 2024 and
2023 is attached as Exhibit 99.3 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Properties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The Company maintains its principal executive
offices at 2 Ha&rsquo;mayan St., Modiin, Israel&nbsp;7177871.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Security Ownership of Certain Beneficial Owners and Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The following table sets forth information known
to the Company regarding the beneficial ownership of New Silexion ordinary shares immediately following the Closing by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">each person who is the beneficial owner of more than 5% of
the outstanding New Silexion ordinary shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s named executive officer and directors;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">all of the Company&rsquo;s executive officers and directors
as a group.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Beneficial ownership
is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she
or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable
or exercisable within 60 days. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership,
the Company deemed outstanding ordinary shares subject to warrants held by that person that are currently exercisable or exercisable within
60 days of the Closing Date. The Company did not deem these shares outstanding, however, for the purpose of computing the percentage ownership
of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Unless otherwise indicated,
the Company believes that all persons named in the table have sole voting and investment power with respect to all New Silexion ordinary
shares beneficially owned by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Unless otherwise indicated,
the address of each beneficial owner listed in the table below is c/o Silexion Therapeutics Corp, 2 Ha&rsquo;mayan St., Modiin, Israel&nbsp;7177871.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">The percentage ownership
of New Silexion ordinary shares is based on 9,768,396 New Silexion ordinary shares outstanding immediately following the Closing, after
giving effect to the various adjustments to the share capital of New Silexion described in the &ldquo;Introductory Note&rdquo; to this
Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><B>Name and Address of Beneficial Owner<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Number of<BR> <U></U>Shares<BR>
Beneficially<BR> Owned</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Approximate<BR> Percentage of<BR>
<U></U>Outstanding Ordinary Shares </B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic">Directors and Executive Officers of New Silexion:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10.25pt">Ilan Hadar</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">280,438</TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Dror Abramov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,829</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD><TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Ruth Alon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,325</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD><TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10.25pt">Ilan Levin<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,066,610</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.8</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10.25pt">Avner Lushi<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,987,082</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10.25pt">Shlomo Noy<SUP>(7)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,987,082</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Ilan Shiloah</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,797</TD><TD STYLE="text-align: left"><SUP>(8)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.2</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Dr.&nbsp;Mitchell Shirvan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,992</TD><TD STYLE="text-align: left"><SUP>(9)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Mirit Horenshtein Hadar, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,772</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD><TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10.25pt">All executive officers and directors as a group (9 individuals)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,089,845</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50.1</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10.25pt">Five Percent Holders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Moringa Sponsor, LP and affiliated entities <SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,066,610</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.8</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Guangzhou Sino-Israel Biotech Fund<SUP>(10)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,987,082</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Wildcat Partner Holdings LP<SUP>(11)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020,852</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.5</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 1%.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="padding-right: 24.3pt; text-align: left">Unless otherwise noted, the business address of each of the following entities or individuals is c/o Silexion Therapeutics Corp, 2 Ha&rsquo;mayan St., Modiin, Israel&nbsp;7177871.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(2)</TD>
    <TD STYLE="text-align: left">Includes 129,045 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD STYLE="text-align: left">The shares reported in this row are held of record by the Sponsor, Moringa Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in footnote (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned&nbsp;by Mr.&nbsp;Ilan Levin, serves as the sole general partner of each of the Sponsor and the PIPE Investor. Mr.&nbsp;Levin, a Director of New Silexion, is the sole director of that general partner. As a result of his ownership of that general partner, Mr.&nbsp;Levin possesses sole voting and investment authority with respect to the shares indirectly held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held by various individuals and entities, including Mr. Levin. Mr.&nbsp;Levin disclaims beneficial ownership of the securities held by the Sponsor and the PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities.&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD STYLE="text-align: left">Consists of the total of: (i)&nbsp;1,337,325 New Silexion ordinary shares issued to the Sponsor as Sponsor Investment Shares; (ii)&nbsp;352,857 New Silexion ordinary shares issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one&nbsp;basis, of the 352,857 Moringa private shares held by it; (iii)&nbsp;176,428 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one&nbsp;basis, of the 176,428 Moringa private warrants held by the Sponsor (which New Silexion warrants will be exercisable beginning 30&nbsp;days after the Closing Date); and (iv) 200,000 New Silexion ordinary shares issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial ownership of New Silexion ordinary shares by the Sponsor does not include any Note&nbsp;Shares that may be issued to the Sponsor following the Closing upon conversion of amounts owed by New Pubco to the Sponsor under the A&amp;R Sponsor Promissory Note, as the potential number of Note&nbsp;Shares, and the timing of issuance of Note&nbsp;Shares, cannot be determined in advance.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: left">The shares reported in this row consist entirely of New Silexion
ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund (&ldquo;GIBF&rdquo;), with respect to which Mr. Lushi possesses
shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: left">Includes 1,835,733 New Silexion ordinary shares issued to
GIBF at the Closing in respect of its transfer of its noncontrolling interest in Silexion&rsquo;s Chinese subsidiary, Silenseed (China)
Ltd., to New Silexion pursuant to the Chinese Subsidiary Transfer.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(7)</TD>
    <TD STYLE="text-align: left">The shares reported in this row consist entirely of New Silexion ordinary shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of his serving as Chief Medical Officer of GIBF.&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 9.35pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD STYLE="text-align: left">Includes 19,914 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $4.17 per share, all of which are vested and currently exercisable.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 9.35pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(9)</TD>
    <TD STYLE="text-align: left">Includes 64,522 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $6.72 per share, all of which are vested and currently exercisable.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 9.35pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(10)</TD>
    <TD STYLE="text-align: left">The address of this shareholder is 34 Ha&rsquo;Barzel St., Tel-Aviv&nbsp;6971052 Israel. Each of Avner Lushi and Shlomo Noy may be deemed to share voting and investment power over the securities beneficially owned by GIBF.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(11)</TD><TD STYLE="text-align: left">The address of this shareholder is 301 Commerce Street, Suite
3150, Fort Worth, Texas 76102. Len Porter may be deemed to have sole voting and investment power over the securities beneficially owned
by Wildcat Partner Holdings LP.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Directors and Executive Officers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Information with respect
to the Company&rsquo;s directors and executive officers after the Closing are described in the Proxy Statement/Prospectus in the section
entitled &ldquo;<I>Management of the Company Following the Business Combination</I>&rdquo; beginning on page 195 thereof and that information
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Board Composition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Upon the Closing, the size of the Board was increased
from two members to seven members. Pursuant to the appointment by New Silexion&rsquo;s shareholders prior to the Closing, the following
persons constitute the Board effective upon the Closing: Ilan Hadar (Chairman), Dror Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo
Noy, and Ilan Shiloah. Biographical information for these individuals is set forth in the Proxy Statement/Prospectus in the section entitled
&ldquo;<I>Management of the Company Following the Business Combination</I>&rdquo; beginning on page 195 thereof, which information is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Director Independence</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Upon the Closing, the
Board determined, based on information provided by each director concerning his background, employment and affiliations, that Messrs.
Dror J. Abramov, Ilan Levin, Avner Lushi, Shlomo Noy and Ilan Shiloah, and Ms. Ruth Alon, representing six of the Company&rsquo;s seven
directors, do not have material relationships with the Company that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director and that each of these directors is &ldquo;independent&rdquo; as that term is defined under the
Nasdaq Listing Rules. In making these determinations, the Board considered the current and prior relationships that each non-employee
director has with the Company and all other facts and circumstances the Board deemed relevant in determining their independence, including
the beneficial ownership of the Company&rsquo;s securities by non-employee directors and the transactions described below under the heading
&ldquo;<I>Certain Relationships and Related Party Transactions</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Committees of the Board of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Effective upon the Closing,
the standing committees of the Board consist of an audit committee, a compensation committee and a corporate governance and nominating
committee. The Board appointed Dror&nbsp;J. Abramov, Ilan Shiloah, and Ruth Alon, with Mr.&nbsp;Abramov serving as chair.&nbsp; The Board
also determined that Mr. Abramov qualifies as an &ldquo;audit committee financial expert&rdquo; within the meaning of the SEC regulations.
The Board appointed Dror J. Abramov, Ilan Shiloah, and Ruth Alon to serve on the compensation committee, with the chair to be chosen subsequently.
The Board appointed Dror J. Abramov, Ilan Levin, Ilan Shiloah, and Ruth Alon to serve on the corporate governance and nominating committee,
with the chair to be chosen subsequently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Executive Officers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Effective as of the
Closing, the Board appointed Ilan Hadar, Mirit Horenshtein Hadar, CPA, and Dr.&nbsp;Mitchell Shirvan to serve as Chief Executive Officer,
Chief Financial Officer, and Chief Scientific and Development Officer, respectively. Biographical information for these individuals is
set forth in the Proxy Statement/Prospectus in the section entitled &ldquo;<I>Management of the Company Following the Business Combination</I>&rdquo;
beginning on page 195 thereof, which information is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Executive Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The compensation of
the Company&rsquo;s named executive officer is described in the Proxy Statement/Prospectus in the section entitled &ldquo;<I>Executive
Compensation</I>&rdquo; beginning on page 202 thereof and that information is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Compensation Committee Interlocks and Insider
Participation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">None of the Company&rsquo;s
officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity that has one or
more officers serving on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Certain Relationships and Related Person
Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Certain relationships
and related person transactions are described in the Proxy Statement/Prospectus in the sections entitled &ldquo;<I>Certain Relationships
and Related Party Transactions</I>&rdquo; beginning on page 209 thereof and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In addition, Ilan&nbsp;Levin,
our director, possesses sole voting and investment authority with respect to the shares held by Greenstar L.P., the PIPE Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Legal Proceedings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The Company has no legal
proceedings to report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Market Price of and Dividends on the
Registrant&rsquo;s Common Equity and Related Shareholder Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Market Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Prior to the Closing,
the Moringa Class A ordinary shares, Moringa warrants and Moringa units were listed on the Nasdaq Capital Market under the symbols &ldquo;MACA&rdquo;,
&ldquo;MACAW&rdquo; and &ldquo;MACAU&rdquo; respectively. Upon the Closing, the New Silexion ordinary shares and New Silexion warrants
were listed on the Nasdaq Global Market under the symbols &ldquo;SLXN&rdquo; and &ldquo;SLXNW&rdquo;, respectively. All outstanding Moringa
units automatically separated into their component securities upon the Closing and, as a result, no longer trade as a separate security
of New Silexion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The Company has not
paid any cash dividends on shares of its ordinary shares to date. The Company currently intends to retain any future earnings and does
not expect to pay any dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion
of the New Silexion Board, subject to applicable laws, and will depend on a number of factors, including the Company&rsquo;s financial
condition, results of operations, capital requirements, contractual restrictions, general business conditions and other factors that the
Board may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Holders of Record</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Following the Closing,
including the redemption of the Moringa public shares described above and the separation of the former Moringa units, there were 33 holders
of record of New Silexion ordinary shares and three holders of record of New Silexion warrants. Such numbers do not include beneficial
owners holding the Company&rsquo;s securities through nominee names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Securities Authorized for Issuance Under
Equity Compensation Plan</I>s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Reference is made to
the disclosure regarding the New Silexion (formerly referred to as the Biomotion Sciences) 2024 Equity Incentive Plan (the &ldquo;2024
Incentive Plan&rdquo;), Silexion&rsquo;s 2013 Share Option Plan&nbsp; and Silexion&rsquo;s 2023 Equity Incentive Plan which is set forth
under the headings &ldquo;<I>2024 Incentive Plan</I>&rdquo;, &ldquo;<I>2023 Equity Incentive Plan</I>&rdquo; and &ldquo;<I>2013 Share
Option Plan&rdquo;</I>, respectively in Item 5.02 of this Report, and which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Recent Sales of Unregistered Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Reference is made to
the disclosure set forth under Item 3.02 of this Report regarding the issuance and sale by the Company of certain unregistered securities,
which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Description of Registrant&rsquo;s Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The Company&rsquo;s
securities are described in the Proxy Statement/Prospectus in the section entitled &ldquo;<I>Description of Securities</I>&rdquo; beginning
on page 216 thereof and that information is incorporated herein by reference. As described below in Item 5.03 of this Report, the Amended
and Restated Memorandum and Articles of the Company became effective as of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Indemnification of Directors and Officers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Information about the
indemnification of the Company&rsquo;s directors and officers is set forth in the Proxy Statement/Prospectus in the section entitled &ldquo;<I>Description
of Securities &mdash; Anti-Takeover Provisions in our Prospective Articles&mdash; Limitation on Liability and Indemnification of Directors
and Officers</I>&rdquo; beginning on page 221 thereof, which information is incorporated herein by reference. The information set forth
under the heading &ldquo;<I>Indemnification Agreements</I>&rdquo; in Item 1.01 of this Report is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 2.03</B> <B>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The information set
forth under the headings &ldquo;<I>Settlement of Amounts Due Under Marketing Agreement with EarlyBird</I>&rdquo;, &ldquo;<I>ELOC Financing</I>&rdquo;
and &ldquo;Amended and Restated Sponsor Promissory Note&rdquo; in Item 1.01 of this Report is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 3.02</B> <B>Unregistered Sales of Equity Securities.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The information set
forth in the &ldquo;<I>Introductory Note</I>&rdquo; and Item 2.01 above with respect to the potential issuance of New Silexion ordinary
shares upon conversion of the EarlyBird Convertible Note, the issuance of the PIPE Shares, the potential issuance of New Silexion ordinary
shares under the ELOC Agreement following the Closing and the potential issuance of Note Shares under the A&amp;R Sponsor Promissory Note
under the headings &ldquo;<I>Settlement of Amounts Due Under Marketing Agreement with EarlyBird</I>&rdquo;, &ldquo;<I>PIPE Financing</I>&rdquo;,
&ldquo;<I>ELOC Financing</I>&rdquo; and &ldquo;<I>Amended and Restated Sponsor Promissory Note<B>&rdquo;</B></I>, respectively, in Item
1.01 of this Report is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">An aggregate of 200,000 New Silexion ordinary
shares were issued to the PIPE Investor in connection with the PIPE Financing immediately prior to the Closing, the prospective issuance
of Note Shares, and the potential issuance of New Silexion ordinary shares upon conversion of the EarlyBird Convertible Note, under the
ELOC Agreement and under the EarlyBird Convertible Note, in each case, has been and will be issued in reliance upon the exemption from
registration provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 3.03</B> <B>Material Modification to Rights of Security Holders.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">The disclosure set forth
under Item 5.03 of this Report is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 5.01</B> <B>Changes in Control of Registrant.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The disclosure set forth
in the &ldquo;<I>Introductory Note</I>&rdquo; above and in Item 2.01 of this Report is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The disclosure set forth
in Item 2.01 of this Report under the headings &ldquo;<I>Directors and Executive Officers</I>,&rdquo; and &ldquo;<I>Executive Compensation</I>&rdquo;
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>2024 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to written resolutions adopted by the Board and shareholders
prior to the Closing, New Silexion has approved and adopted the 2024 Equity Incentive Plan (the &ldquo;2024 Plan&rdquo;), which became
effective immediately upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Upon the Closing, a total of 575,572 New Silexion
ordinary shares were reserved for issuance under the terms of the 2024 Incentive Plan, which, together with New Silexion ordinary shares
allocated for issuance under the existing Silexion 2013 Share Option Plan and Silexion 2023 Equity Incentive Plan, equaled 10% of the
total number of New Silexion ordinary shares on a fully diluted basis immediately following the Closing. A summary of the other material
terms of the 2024 Incentive Plan is provided below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><I>Administration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The compensation committee of our Board is the
administrator of the 2024 Plan. Except as provided otherwise under the 2024 Plan, the administrator has plenary authority to grant awards
pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares covered by the
awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the purpose and intent
of the 2024 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><I>Eligibility and Participation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The administrator selects the individuals who
participate in the 2024 Plan. Eligibility to participate is open to officers, directors and employees of, and other individuals who provide
bona fide services to or for, us or any of our subsidiaries. Our Board may also select as participants prospective officers, employees
and individual service providers who have accepted an offer of employment or another service relationship from us or one of our subsidiaries.
Any awards granted to such a prospect before the individual&rsquo;s start date may not become vested or exercisable, and no shares may
be issued to such individual, before the date the individual first commences performance of services with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>Share Pool Under the 2024 Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The initial number of New Silexion ordinary shares
allocated to the 2024 Plan is 575,572. The number of New Silexion ordinary shares available under the 2024 Plan (the &ldquo;Share Pool&rdquo;)
will be subject to the following annual allocations and adjustments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The Share Pool will be increased automatically
on January 1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including)
January 1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of
that January 1 date, or (ii) an amount determined by our Board prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The following additional rules apply to the number
of New Silexion ordinary shares available under the Share Pool on an ongoing basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The Share Pool will be reduced by one share for each share
made subject to an award granted under the 2024 Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The Share Pool will be increased by the number of unissued
shares underlying or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled,
forfeited, expired, terminated unearned or settled in cash, in any such case without the issuance of shares;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The Share Pool will be increased by the number of shares that
are forfeited back to us after issuance due to a failure to meet an award contingency or condition with respect to any award or portion
of an award granted under the 2024 Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The Share Pool shall be increased, on the exercise date, by
the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price
of any award granted under the 2024 Plan; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The Share Pool shall be increased, on the relevant date, by
the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding
obligation that arises in connection with any award granted under the 2024 Plan.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">In the event of a merger, consolidation, share
rights offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split,
separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization
or similar event affecting the capital structure of the Company, our Board will make equitable and appropriate substitutions or proportionate
adjustments to the Share Pool to reflect the transaction or event. Similar adjustments will be made to the award limitations described
below and to the terms of outstanding awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ISO Award Limit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The maximum number of New Silexion ordinary shares
that may be issued in connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options under
Section 422 of the Code is 575,572.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Types of Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>General</I>. The 2024 Plan enables the grant
of share awards, performance shares, restricted share units, cash-based performance units, other share-based awards, share options, share
appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other awards. The administrator
may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for recipients in jurisdictions
outside the U.S. may be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">New Silexion has adopted a sub-plan for Israeli
participants, which provides for granting awards in compliance with Section 102 (&ldquo;Section 102&rdquo;) and Section 3(i) of the Israeli
Income Tax Ordinance (New Version), 5721-1961, as amended (the &ldquo;ITO&rdquo;). Section 102 allows employees, directors and officers
who are not controlling shareholders and who are considered Israeli residents for tax purposes to receive favorable tax treatment for
compensation in the form of shares, options or certain other types of equity awards, subject to certain terms and conditions. Our non-employee
service providers and controlling shareholders who are considered Israeli residents for tax purposes may be granted awards under Section
3(i) of the ITO, which do not provide for similar tax benefits as Section 102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Out of the three tax tracks that are available
under Section 102 ((i) the &ldquo;ordinary income track&rdquo; with a trustee, (ii) the &ldquo;capital gains track&rdquo; with a trustee
and (iii) grants without a trustee and without a trust period), New Silexion has elected the &ldquo;capital gain track&rdquo; for grants
to eligible Israeli grantees as provided above, which may allow favorable tax treatment for such grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Adjustments to Awards for Corporate Transactions and Other Events</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><I>Mandatory Adjustments</I>. In the event of
a merger, amalgamation, consolidation, share rights offering, share exchange or similar event affecting the Company (a &ldquo;Corporate
Event&rdquo;) or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash
or other property, share combination or subdivision, or recapitalization, capital reduction distribution or similar event affecting the
capital structure of the Company, the administrator will make equitable and appropriate substitutions or proportionate adjustments to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the aggregate number and kind of shares or other securities
that may be granted to eligible individuals under the 2024 Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the maximum number of shares or other securities that may
be issued with respect to incentive share options granted under the 2024 Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the number of shares or other securities covered by each outstanding
award and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">all other numerical limitations relating to awards, whether
contained in the 2024 Plan or in award agreements.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Notwithstanding the foregoing, any fractional
shares resulting from the above mandatory adjustments will be eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Discretionary Adjustments</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">In addition to the adjustments specified above,
in the case of Corporate Events, the administrator may make such other adjustments to outstanding awards as it determines to be appropriate
and desirable, which adjustments may include, without limitation, (i)&nbsp;the cancellation of outstanding awards in exchange for payments
of cash, securities or other property or a combination thereof having an aggregate value equal to the value of such awards, (ii)&nbsp;the
substitution of securities or other property (including, without limitation, cash or other securities of the Company and securities of
entities other than the Company) for the shares subject to outstanding awards, and (iii)&nbsp;the substitution of equivalent awards, as
determined in the sole discretion of the administrator, of the surviving or successor entity or a parent thereof. The administrator may,
in its discretion, adjust the performance goals applicable to any awards to reflect any unusual or non-recurring events and other extraordinary
items, impact of charges for restructurings, discontinued operations and the cumulative effects of accounting or tax changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Repricing</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The administrator may reprice any share options
or share appreciation rights without the approval of the shareholders of the Company. For this purpose, &ldquo;reprice&rdquo; means (i)&nbsp;any
of the following or any other action that has the same effect: (A)&nbsp;lowering the exercise price or base price of an option or share
appreciation right after it is granted other than an adjustment made pursuant to the provisions of the 2024 Plan, (B)&nbsp;any other action
that is treated as a repricing under applicable accounting principles; (C)&nbsp;cancelling a share option or share appreciation right
at a time when its exercise price or base price exceeds the fair market value of the underlying share, in exchange for another share option,
share appreciation right, restricted share or other equity, unless the cancellation and exchange occurs in connection with a merger, acquisition,
spin-off or other similar corporate transaction; and (ii)&nbsp;any other action that is considered to be a repricing under formal or informal
guidance issued by the primary securities market or exchange on which the shares are listed or admitted for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Treatment of Awards upon Dissolution or Liquidation or a Change
in Control</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dissolution or Liquidation</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Unless the administrator determines otherwise,
all awards outstanding under the 2024 Plan will terminate upon the dissolution or liquidation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amendment and Termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">Our Board or the compensation committee may terminate,
amend or modify the 2024 Plan or any portion of it at any time; provided, that, (i) if required to comply with Cayman Islands law and
any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other than any requirement from
which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder approval of any 2024
Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially impair the
rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or the rules
of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to the Company
or the participant) without such participant&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The 2024 Plan is scheduled to expire on August
14, 2034, which is ten years after the effective date of its adoption by our Board. After that time, no further grants may be made under
the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The foregoing description of the 2024 Incentive
Plan is qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached to this Report as Exhibit 10.12 and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 5.03 Amendments to Articles of
Incorporation or Bylaws; Change in Fiscal Year.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">On the effectiveness
of the SPAC Merger, the Company amended and restated its memorandum and articles of association (as amended and restated, the &ldquo;Amended
and Restated Memorandum and Articles of Association&rdquo;), which became effective upon adoption by New Silexion&rsquo;s sole shareholder
at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">A copy of the Amended
and Restated Memorandum and Articles of Association is attached to this Report as Exhibit 3.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">The material terms of
the Amended and Restated Memorandum and Articles of Association and the general effect upon the rights of holders of the Company&rsquo;s
share capital, are described in the sections of the Proxy Statement/Prospectus titled &ldquo;<I>Description of Securities</I>&rdquo; and
&ldquo;<I>Comparison of Shareholders&rsquo; Rights</I>&rdquo; beginning on pages 216 and 222, respectively, thereof, which information
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 5.05</B> <B>Amendments to the Registrant&rsquo;s Code of Ethics, or Waiver of a Provision of the Code of Ethics.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">On the Closing Date,
in connection with the Closing, the Board adopted a new code of business conduct and ethics applicable to all of the Company&rsquo;s directors,
officers and employees. A copy of the code of business conduct and ethics is available on the investor relations portion of the Company&rsquo;s
website at www.silexion.com. The foregoing description of the code of business conduct and ethics does not purport to be complete and
is qualified in its entirety by the full text of the code of business conduct and ethics, a copy of which is attached to this Report as
Exhibit 14.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Item 5.06</B> <B>Change in Shell Company Status.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">As a result of the Business
Combination, the Company ceased to be a shell company. Reference is made to the disclosure in the Proxy Statement/Prospectus in the section
entitled &ldquo;<I>Proposal No. 1 &mdash; The Business Combination Proposal</I>&rdquo; beginning on page 101 thereof, which is incorporated
by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 7.01</B> <B>Regulation FD Disclosure.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">On August 15, 2024,
the Company issued a press release announcing, among other things, the Closing. The press release is attached to this Report as Exhibit
99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">The information contained
under this Item 7.01 in this Report, including Exhibit 99.1, is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Exchange Act or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated
by reference into any filing of the Company under the Securities Act or the Exchange Act, except as may be expressly set forth by specific
reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 9.01 Financial Statements and
Exhibits.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(a)</B> <B>Financial statements of businesses or funds acquired.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">The unaudited condensed
consolidated financial statements of Silexion as of June 30, 2024, and for the three and six months periods ended, June 30, 2024 and 2023,
are set forth in Exhibit 99.1 attached hereto and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(b)</B> <B>Pro forma financial information.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">The pro forma condensed combined financial information
of the Company as of June 30, 2024, and for the year ended December 31, 2023 and six months ended June 30, 2024 is attached as Exhibit
99.2 to this Report and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(d)</B> <B>Exhibits.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom; width: 9%"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 90%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">2.1.1&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea020320401ex2-1_moringaacq.htm">Amended and Restated Business Combination Agreement, dated as of April&nbsp;3, 2024, by and among Biomotion Sciences, August M.S.&nbsp;Ltd., Moringa Acquisition Merger Sub Corp, Silexion Therapeutics Ltd. and Moringa Acquisition Corp (incorporated by reference to Exhibit 2.1 to Moringa Acquisition Corp&rsquo;s Current Report on Form 8-K, filed with the SEC on April 3, 2024)</A></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">2.1.2</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1835416/000121390024055254/ea020833801ex10-1_moringa.htm">Waiver letter, dated June 18, 2024, under Amended and Restated Business Combination Agreement (incorporated by reference to Exhibit 10.1 to Moringa Acquisition Corp&rsquo;s Current Report on Form 8-K filed with the SEC on June 24, 2024)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">2.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex2-2_silexion.htm">Plan of Merger for merger of Moringa Acquisition Corp and Moringa Acquisition Merger Sub Corp</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">3.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex3-1_silexion.htm">Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">4.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex4-1_silexion.htm">Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and Continental Stock Transfer &amp; Trust Company.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">10.1.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-1i_silexion.htm">Final invoice issued by EarlyBirdCapital, Inc. to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February 16, 2021, by and between EarlyBirdCapital, Inc. and Moringa Acquisition Corp</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">10.1.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-1ii_silexion.htm">Convertible Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to EarlyBirdCapital, Inc.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">10.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-2_silexion.htm">Subscription Agreement, dated August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and Greenstar, L.P.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">10.3.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-3i_silexion.htm">Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">10.3.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-3ii_silexion.htm">Registration Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">10.4*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-4_silexion.htm">Amended and Restated Registration Rights and Lock-Up&nbsp;Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.&rsquo;s pre-Business Combination shareholders and Greenstar, L.P.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">10.5*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-5_silexion.htm">Amended and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa Sponsor, L.P.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">10.6*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-6_silexion.htm">Form of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and each of its executive officers and directors</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.11.1#</P></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm">Employment Agreement, dated April&nbsp;1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1 to Amendment No. 3 to the Company&rsquo;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024).</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.11.2#</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm">Amendment No. 1 to Employment Agreement, dated May&nbsp;2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar ((incorporated by reference to Exhibit 10.12.2 to Amendment No. 3 to the Company&rsquo;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">10.12#*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex10-12_silexion.htm">Silexion Therapeutics Corp 2024 Equity Incentive Plan</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">14.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex14-1_silexion.htm">Silexion Therapeutics Corp Code of Ethics and Business Conduct</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">21.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex21-1_silexion.htm">List of Subsidiaries.</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">99.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex99-1_silexion.htm">Unaudited condensed consolidated financial statements of Silexion as of June 30, 2024, and for the three and six months periods ended, June 30, 2024 and 2023</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">99.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex99-2_silexion.htm">Unaudited pro forma condensed combined financial information of the Company as of June 30, 2024, and for the year ended December 31, 2023 and six months ended June 30, 2024</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">99.3*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex99-3_silexion.htm">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations of Silexion Therapeutics Ltd. covering the three and six months periods ended, June 30, 2024 and 2023</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">99.4*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021197601ex99-4_silexion.htm">Press release, dated August 15, 2024, announcing the closing of the Business Combination</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&dagger;</TD>
    <TD>Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">#</TD>
    <TD STYLE="text-align: justify">Indicates management contract or compensatory plan, contract or arrangement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>SILEXION THERAPEUTICS CORP</B></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: August 21, 2024</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Ilan Hadar</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 35%"> Ilan Hadar</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
